Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lo

Showing results (1061-1070 of 1,300) with videos related to

Pageof 130
Sort By:
Nature Communications|December 16, 2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanomaJudith Müller, Oscar Krijgsman, Jennifer Tsoi, et al.
ESMO Open|July 6, 2026
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancerI Schlam, D Trapani, S-E Kim, et al.
Nature Cell Biology|September 13, 2016
Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylationMin Pan, Michael A Reid, Xazmin H Lowman, et al.
Journal of Translational Medicine|April 22, 2010
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032Jonas N Søndergaard, Ramin Nazarian, Qi Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2026
Defining the Role of SABR in Head and Neck Cancer: Results from a Multi-institutional Delphi ConsensusClaire Petit, Jack Phan, Sweet Ping Ng, et al.
Nature|July 6, 2012
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionRavid Straussman, Teppei Morikawa, Kevin Shee, et al.
Cancer Discovery|November 23, 2013
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapyHubing Shi, Willy Hugo, Xiangju Kong, et al.
Oncogene|October 10, 2017
Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness propertiesC-H Wang, P-J Wang, Y-C Hsieh, et al.
Head & Neck|April 25, 2025
Dual PD-1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland CancersCristina P Rodriguez, Qian Vicky Wu, Kevin Ng, et al.
Neuro-Oncology|February 5, 2016
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant gliomaLee A Wheeler, Andrea G Manzanera, Susan D Bell, et al.
Pageof 130

Showing results (1061-1070 of 1,300) with videos related to

Sort By:
Pageof 130
Nature Communications|December 16, 2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanomaJudith Müller, Oscar Krijgsman, Jennifer Tsoi, et al.
ESMO Open|July 6, 2026
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancerI Schlam, D Trapani, S-E Kim, et al.
Nature Cell Biology|September 13, 2016
Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylationMin Pan, Michael A Reid, Xazmin H Lowman, et al.
Journal of Translational Medicine|April 22, 2010
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032Jonas N Søndergaard, Ramin Nazarian, Qi Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2026
Defining the Role of SABR in Head and Neck Cancer: Results from a Multi-institutional Delphi ConsensusClaire Petit, Jack Phan, Sweet Ping Ng, et al.
Nature|July 6, 2012
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionRavid Straussman, Teppei Morikawa, Kevin Shee, et al.
Cancer Discovery|November 23, 2013
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapyHubing Shi, Willy Hugo, Xiangju Kong, et al.
Oncogene|October 10, 2017
Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness propertiesC-H Wang, P-J Wang, Y-C Hsieh, et al.
Head & Neck|April 25, 2025
Dual PD-1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland CancersCristina P Rodriguez, Qian Vicky Wu, Kevin Ng, et al.
Neuro-Oncology|February 5, 2016
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant gliomaLee A Wheeler, Andrea G Manzanera, Susan D Bell, et al.
Pageof 130